Literature DB >> 8751853

Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities.

D M Parry1, M M MacCollin, M I Kaiser-Kupfer, K Pulaski, H S Nicholson, M Bolesta, R Eldridge, J F Gusella.   

Abstract

Neurofibromatosis 2 (NF2) features bilateral vestibular schwannomas, other benign neural tumors, and cataracts. Patients in some families develop many tumors at an early age and have rapid clinical progression, whereas in other families, patients may not have symptoms until much later and vestibular schwannomas may be the only tumors. The NF2 gene has been cloned from chromosome 22q; most identified germ-line mutations result in a truncated protein and severe NF2. To look for additional mutations and clinical correlations, we used SSCP analysis to screen DNA from 32 unrelated patients. We identified 20 different mutations in 21 patients (66%): 10 nonsense mutations, 2 frameshifts, 7 splice-site mutations, and 1 large in-frame deletion. Clinical information on 47 patients from the 21 families included ages at onset and at diagnosis, numbers of meningiomas, spinal and skin tumors, and presence of cataracts and retinal abnormalities. We compared clinical findings in patients with nonsense or frameshift mutations to those with splice-site mutations. When each patient was considered as an independent random event, the two groups differed (P < or = .05) for nearly every variable. Patients with nonsense or frameshift mutations were younger at onset and at diagnosis and had a higher frequency and mean number of tumors, supporting the correlation between nonsense and frameshift mutations and severe NF2. When each family was considered as an independent random event, statistically significant differences between the two groups were observed only for mean ages at onset and at diagnosis. A larger data set is needed to resolve these discrepancies. We observed retinal hamartomas and/or epiretinal membranes in nine patients from five families with four different nonsense mutations. This finding, which may represent a new genotype-phenotype correlation, merits further study.

Entities:  

Mesh:

Year:  1996        PMID: 8751853      PMCID: PMC1914910     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  52 in total

1.  Early-onset neuroma: genetic, clinical and nosologic aspects.

Authors:  J C Allen; R Eldridge; D Young
Journal:  Birth Defects Orig Artic Ser       Date:  1974

2.  Familial central nervous system neoplasia. Case report of a family with von Recklinghausen's neurofibromatosis.

Authors:  D K Lee; M L Abbott
Journal:  Arch Neurol       Date:  1969-02

3.  Use of cyclosporin A in establishing Epstein-Barr virus-transformed human lymphoblastoid cell lines.

Authors:  M A Anderson; J F Gusella
Journal:  In Vitro       Date:  1984-11

4.  Combined hamartomas of the retina and retinal pigment epithelium.

Authors:  A P Schachat; J A Shields; S L Fine; G E Sanborn; T A Weingeist; R E Valenzuela; A J Brucker
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

5.  Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22.

Authors:  G A Rouleau; W Wertelecki; J L Haines; W J Hobbs; J A Trofatter; B R Seizinger; R L Martuza; D W Superneau; P M Conneally; J F Gusella
Journal:  Nature       Date:  1987 Sep 17-23       Impact factor: 49.962

6.  [A family of von Recklinghausen's neurofibromatosis complicated by mononeuritis multiplex, bilateral acoustic neurinomas, and falx and spinal meningiomas].

Authors:  M Mori; S Morisaki; R Hazama; M Tsujihata; S Nagataki; M Yonekura; T Moriyama; K Mori
Journal:  No To Shinkei       Date:  1985-04

7.  Café-au-lait spots of the fundus in neurofibromatosis.

Authors:  E Cotlier
Journal:  Arch Ophthalmol       Date:  1977-11

8.  Mutational analysis of patients with neurofibromatosis 2.

Authors:  M MacCollin; V Ramesh; L B Jacoby; D N Louis; M P Rubio; K Pulaski; J A Trofatter; M P Short; C Bove; R Eldridge
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

Review 9.  Neurofibromatosis 2 (bilateral acoustic neurofibromatosis).

Authors:  R L Martuza; R Eldridge
Journal:  N Engl J Med       Date:  1988-03-17       Impact factor: 91.245

10.  Central neurofibromatosis with bilateral acoustic neuroma: genetic, clinical and biochemical distinctions from peripheral neurofibromatosis.

Authors:  W R Kanter; R Eldridge; R Fabricant; J C Allen; T Koerber
Journal:  Neurology       Date:  1980-08       Impact factor: 9.910

View more
  41 in total

Review 1.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

2.  The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.

Authors:  Anne-Marie Bashour; J-J Meng; Wallace Ip; Mia MacCollin; Nancy Ratner
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

3.  Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas.

Authors:  C L Wu; N Thakker; W Neary; G Black; R Lye; R T Ramsden; A P Read; D G Evans
Journal:  J Med Genet       Date:  1998-12       Impact factor: 6.318

Review 4.  The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.

Authors:  M E Baser; L Kuramoto; R Woods; H Joe; J M Friedman; A J Wallace; R T Ramsden; S Olschwang; E Bijlsma; M Kalamarides; L Papi; R Kato; J Carroll; C Lázaro; F Joncourt; D M Parry; G A Rouleau; D G R Evans
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

5.  Effects of splicing mutations on NF2-transcripts: transcript analysis and information theoretic predictions.

Authors:  James R Ellis; Bianca Heinrich; Victor-F Mautner; Lan Kluwe
Journal:  Genes Chromosomes Cancer       Date:  2011-05-11       Impact factor: 5.006

6.  Predictors of the risk of mortality in neurofibromatosis 2.

Authors:  Michael E Baser; J M Friedman; Dana Aeschliman; Harry Joe; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2002-08-22       Impact factor: 11.025

7.  Development of NF2 gene specific, strictly sequence defined diagnostic microarray for deletion detection.

Authors:  Kiran K Mantripragada; Patrick G Buckley; Caroline Jarbo; Uwe Menzel; Jan P Dumanski
Journal:  J Mol Med (Berl)       Date:  2003-06-27       Impact factor: 4.599

8.  Identification of mutations in the NF2 gene in Polish patients with neurofibromatosis type 2.

Authors:  Mikołaj Łaniewski-Wołłk; Monika Gos; Andrzej Koziarski; Agnieszka Szpecht-Potocka
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

9.  Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study.

Authors:  Michael E Baser; Lisa Kuramoto; Harry Joe; J M Friedman; Andrew J Wallace; James E Gillespie; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2004-06-09       Impact factor: 11.025

Review 10.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.